Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

SRRK
Scholar Rock Holding Corporation Common Stock
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
30.51USD-1.038%(-0.32)1,075,653
30.43Bid   30.49Ask   0.06Spread
Pre-market
May 15, 2025 8:42:30 AM EDT
30.00USD-2.692%(-0.83)0
After-hours
May 16, 2025 4:00:30 PM EDT
30.55USD+0.131%(+0.04)2,427
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
08:30AM EST  Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGF for Immuno-Oncology Drug Development Summit   Business Wire
Jan 10, 2022
07:30AM EST  Scholar Rock Provides Corporate Update and Highlights Priorities for 2022   Business Wire
Jan 4, 2022
04:01PM EST  Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference   Business Wire
Dec 22, 2021
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021   Benzinga
05:39AM EST  Jefferies Downgrades Scholar Rock Holding to Hold, Lowers Price Target to $28   Benzinga
Nov 30, 2021
05:04PM EST  Scholar Rock Announces Design Of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab In Non-Ambulatory Patients With Type 2 And Type 3 Spinal Muscular Atrophy   Benzinga
04:05PM EST  Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)   Business Wire
Nov 19, 2021
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021   Benzinga
04:51AM EST  Piper Sandler Initiates Coverage On Scholar Rock Holding with Overweight Rating, Announces Price Target of $56   Benzinga
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:14AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:05AM EST  Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B   Business Wire
Nov 9, 2021
11:43AM EST  Scholar Rock Holding Q3 EPS $(1.02) Down From $(0.79) YoY, Sales $5.46M Up From $3.04M YoY   Benzinga
08:13AM EST  Scholar Rock Q3 Net Loss $37.5 Mln Or $1.02/shr Vs Net Loss Of $23.6 Mln Or $0.79/shr Prior Year   RTTNews
08:05AM EST  Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress   Business Wire
Nov 2, 2021
04:01PM EDT  Scholar Rock to Present at Upcoming Healthcare Conferences   Business Wire
Oct 3, 2021
09:33AM EDT  Scholar Rock To Present Apitegromab TOPAZ Phase 2 Pharmacologic Data   RTTNews
09:03AM EDT  Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology   Benzinga
Sep 30, 2021
11:45AM EDT  Scholar Rock Presents Exploratory Responder Analysis On Efficacy Data From Apitegromab TOPAZ Phase 2 Trial At Child Neurology Society Annual Meeting   Benzinga
11:45AM EDT  Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting   Business Wire
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 28, 2021
04:03PM EDT  SCholar Rock Reports US Patent Issued Protecting SRK-181 As Inhibitor Of TGF1 Activation   Benzinga
04:01PM EDT  Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGF1 Activation   Business Wire
Sep 23, 2021
11:33AM EDT  Scholar Rock Presents Additional Data Analyses From Apitegromab TOPAZ Phase 2 Trial At World Muscle Society 2021 Virtual Congress   Benzinga
11:31AM EDT  Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress   Business Wire
Sep 22, 2021
04:01PM EDT  Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference   Business Wire
Aug 16, 2021
04:09PM EDT  Scholar Rock Appoints Caryn Parlavecchio As Chief Human Resources Officer   RTTNews
Aug 13, 2021
10:07PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation (Scholar Rock or the Company) (NASDAQ:SRRK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Aug 10, 2021
04:41PM EDT  Scholar Rock Holding Q2 EPS $(0.84) Down From $(0.65) YoY, Sales $4.60M Up From $3.90M YoY   Benzinga
04:15PM EDT  Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress   Business Wire
Aug 5, 2021
04:01PM EDT  Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference   Business Wire
Aug 3, 2021
07:34AM EDT  Scholar Rock CEO Tony Kingsley Departs, Nagesh Mahanthappa Appointed Interim CEO   Benzinga
07:30AM EDT  Scholar Rock Announces Leadership Change   Business Wire
Jun 18, 2021
08:08AM EDT  Scholar Rock To Present Apitegromab TOPAZ Phase 2 Trial Results At 2021 European Academy Of Neurology Congress   RTTNews
08:01AM EDT  Scholar Rock To Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic And Pharmacodynamic Data At 2021 European Academy Of Neurology Congress Jun. 19-22   Benzinga
08:00AM EDT  Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress   Business Wire
Jun 11, 2021
07:31AM EDT  Scholar Rock Highlights Presentation Of TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting   Benzinga
07:30AM EDT  Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting   Business Wire
Jun 7, 2021
07:57AM EDT  Scholar Rock To Present Apitegromab Clinical Data From TOPAZ Phase 2 Trial In Type 2 & 3 Spinal Muscular Atrophy At SMA   RTTNews
07:37AM EDT  Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting   Benzinga
May 27, 2021
08:01AM EDT  Scholar Rock to Present at Upcoming Healthcare Conferences in June   Business Wire
May 25, 2021
06:44AM EDT  A Peek Into The Markets: US Stock Futures Rise Ahead Of Economic Reports   Benzinga
May 24, 2021
04:12PM EDT  Scholar Rock's Apitegromab Gets Fast Track Designation From FDA For Spinal Muscular Atrophy Treatment   RTTNews
04:06PM EDT  Scholar Rock Reports FDA Fast Track Designation For Apitegromab For Treatment Of Patients With Spinal Muscular Atrophy   Benzinga
04:05PM EDT  Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy   Business Wire
May 19, 2021
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
05:05PM EDT  Scholar Rock to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting   Business Wire
May 13, 2021
07:45AM EDT  Scholar Rock Q1 Loss Per Share $0.76 Vs Loss Per Share $0.58 Prior Year   RTTNews
07:31AM EDT  Scholar Rock Holding Q1 EPS $(0.76) Down From $(0.58) YoY, Sales $4.70M Down From $5.03M YoY   Benzinga
07:30AM EDT  Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress   Business Wire
May 11, 2021
04:49PM EDT  Scholar Rock Highlights Publication Of Phase 1 Data Evaluating Apitegromab In Healthy Volunteers In Journal Advances In Therapy   Benzinga
04:30PM EDT  Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy   Business Wire
Apr 27, 2021
07:41AM EDT  The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout   Benzinga
Apr 26, 2021
04:59PM EDT  Scholar Rock Reports Issuance Of US Patent Broadly Relevant To Inhibitors Of Myostatin Activation   Benzinga
04:59PM EDT  Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation   Business Wire
Apr 24, 2021
09:45PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation (Scholar Rock or the Company) (NASDAQ: SRRK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Apr 12, 2021
10:01AM EDT  Scholar Rock Saturday Morning Announced Biomarker Strategy To Support SRK-181 DRAGON Phase 1 Proof-Of-Concept Trial At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting   Business Wire
Apr 6, 2021
02:51PM EDT  Mid-Afternoon Market Update: Dow Falls 50 Points; Scienjoy Shares Spike Higher   Benzinga
12:33PM EDT  Mid-Day Market Update: Crude Oil Rises Over 2%; Scholar Rock Shares Plunge   Benzinga
12:17PM EDT  Why Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular Atrophy   Benzinga
10:24AM EDT  Mid-Morning Market Update: Markets Edge Higher; Paychex Profit Tops Views   Benzinga
07:48AM EDT  Scholar Rock Reports Apitegromab Data In Spinal Muscular Atrophy   Benzinga
07:09AM EDT  Scholar Rock Announces Positive 12-Month Top-Line Results From The TOPAZ Phase 2 Clinical Trial   RTTNews
07:02AM EDT  Scholar Rock Announces 12-Month Top-Line Results From TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab In Patients With Type 2 And Type 3 Spinal Muscular Atrophy   Benzinga
07:00AM EDT  Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)   Business Wire
Mar 22, 2021
04:21PM EDT  Scholar Rock Announces Publication Of Preclinical Pharmacology, Pharmacokinetics, And Safety Profile Of SRK-181 In The International Journal Of Toxicology   Benzinga
Mar 18, 2021
04:05PM EDT  Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors   Business Wire
Mar 17, 2021
04:09PM EDT  Scholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscular Atrophy   Benzinga
Mar 15, 2021
08:14AM EDT  Scholar Rock To Present TOPAZ Interim Analysis Data For Apitegromab in Spinal Muscular Atrophy At 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference Mar. 18   Benzinga
08:00AM EDT  Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference   Business Wire
Mar 9, 2021
04:12PM EST  Scholar Rock Holding Reports FY20 EPS $(2.81) Down From $(1.85) YoY, Sales $15.4030M Down From $20.492M YoY   Benzinga
04:05PM EST  Scholar Rock Reports Full Year 2020 Financial Results and Highlights Business Progress   Business Wire
Feb 4, 2021
04:30PM EST  Scholar Rock Announces Senior Management Promotions   Business Wire
Jan 27, 2021
08:08AM EST  Scholar Rock Presents Preclinical Data For SRK-181 At TGF For Immuno-Oncology Drug Development Summit   RTTNews
08:03AM EST  Scholar Rock Highlights Presentation Of Pre-Clinical Data For SRK-181 At TGF for Immuno-Oncology Drug Development Summit On Jan. 28, 2021 At 12:30 p.m. EST   Benzinga
08:00AM EST  Scholar Rock Presents Preclinical Data for SRK-181 at the TGF for Immuno-Oncology Drug Development Summit   Business Wire
Jan 11, 2021
10:06AM EST  Benzinga's Top Upgrades, Downgrades For January 11, 2021   Benzinga
07:42AM EST  Scholar Rock Provides Corporate Update And Highlights Priorities for 2021   Benzinga
06:32AM EST  Credit Suisse Initiates Coverage On Scholar Rock Holding with Outperform Rating, Announces Price Target of $65   Benzinga
Jan 6, 2021
10:14AM EST  Benzinga's Top Upgrades, Downgrades For January 6, 2021   Benzinga
07:43AM EST  JP Morgan Initiates Coverage On Scholar Rock Holding with Overweight Rating, Announces Price Target of $59   Benzinga
Jan 4, 2021
04:01PM EST  Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference   Business Wire
Nov 12, 2020
08:00AM EST  Scholar Rock to Present at Upcoming Healthcare Conferences   Business Wire
Nov 9, 2020
08:23AM EST  Scholar Rock Q3 Net Loss $23.6 Mln Vs. Net Loss $16.1 Mln Last Year   RTTNews
08:23AM EST  Seagen Highlights Immuno-Oncology Data From Broad Portfolio During SITC Virtual Annual Meeting 2020   Benzinga
08:17AM EST  Scholar Rock Holding Q3 EPS $(0.79) Down From $(0.55) YoY, Sales $3.04M Down From $4.77M YoY   Benzinga
08:00AM EST  Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress   Business Wire
Nov 5, 2020
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
Nov 4, 2020
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
Nov 2, 2020
04:05PM EST  Scholar Rock Announces Closing of Public Offering of Common Stock and Prefunded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares   Business Wire
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 30, 2020
07:43AM EDT  Scholar Rock 8-K Shows Co. Terminates Sale Deal With Jefferies   Benzinga
Oct 29, 2020
08:53AM EDT  Stocks Trading Near 52-Week Highs Before Open On Thursday, Oct. 29, 2020: CARR, COWN, HUSN, SNE, TWTR, SRRK, IPHI, PINS   Benzinga
07:43AM EDT  Scholar Rock Shares Spiking over $45 Level Premarket After Co Priced Offering @$39/Share Late Wednesday   Benzinga
Oct 28, 2020
11:27PM EDT  Scholar Rock Holding Prices Underwritten Public Offering Of 2.95 Mln At $39.00/shr   RTTNews
10:33PM EDT  Scholar Rock Announces Pricing of Public Offering of Common Stock and Prefunded Warrants   Business Wire
10:37AM EDT  Shares of Scholar Rock Holding Corporation (SRRK) are rising more than 15% Wednesday morning, continuing the momentum from yesterday.   RTTNews
08:59AM EDT  Stocks Trading Near 52-Week Highs Before Open On Wednesday, Oct. 28, 2020: BG, ALACW, FSLR, SRRK   Benzinga
Oct 27, 2020
04:50PM EDT  Source Familiar With Matter Tells Benzinga Pricing Of Scholar Rock Offering Expected Wednesday Night Or Thursday Morning   Benzinga
04:39PM EDT  Scholar Rock Announces $150M Public Offering of Common Stock   Benzinga
04:17PM EDT  Scholar Rock Announces Proposed Public Offering of Common Stock   Business Wire
02:31PM EDT  Mid-Afternoon Market Update: Crude Oil Rises 3%; Scholar Rock Shares Spike Higher   Benzinga
12:19PM EDT  Mid-Day Market Update: Harley-Davidson Jumps Following Strong Q3 Results; Catabasis Pharmaceuticals Shares Plummet   Benzinga
10:55AM EDT  Mid-Morning Market Update: Markets Mostly Lower; 3M Tops Q3 Estimates   Benzinga
10:05AM EDT  Shares of Scholar Rock Holding Corp. (SRRK) surged over 45% on Tuesday morning after the clinical-stage biopharmaceutical company announced positive data from phase 2 trial of spinal muscular atrophy treatment.   RTTNews
07:24AM EDT  Scholar Rock Announces Proof-Of-Concept Data From TOPAZ Phase 2 Trial Interim Analysis Of SRK-015 In Patients With Type 2 And Type 3 Spinal Muscular Atrophy   Benzinga
07:00AM EDT  Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy   Business Wire
Oct 19, 2020
07:30AM EDT  Scholar Rock Secures $50 million Debt Facility with Silicon Valley Bank and Oxford Finance   Business Wire
Sep 30, 2020
07:36AM EDT  Scholar Rock To Present Data For SRK-015 At The World Muscle Society 2020 Virtual Congress Oct. 1   Benzinga
Sep 9, 2020
07:37AM EDT  Scholar Rock Announces First Patient Dosed In Part A2 Of DRAGON Phase 1 Proof-Of-Concept Trial Of SRK-181 To Overcome Primary Resistance To Anti-PD-(L)1 Therapy   Benzinga
Sep 2, 2020
04:30PM EDT  Scholar Rock to Present at Upcoming Healthcare Conferences   Business Wire
Aug 27, 2020
07:38AM EDT  Scholar Rock Announces Issuance Of US Patent Providing Composition Of Matter Protection For SRK-015   Benzinga
Aug 13, 2020
07:34AM EDT  Scholar Rock Reports SRK-015 Received FDA Rare Pediatric Disease Designation For Treatment Of Spinal Muscular Atrophy   Benzinga
Aug 7, 2020
07:28AM EDT  Scholar Rock Q2 Net Loss $19.3 Mln Or $0.65/Shr Vs Loss Of $12.5 Mln Or $0.48/Shr Last Year   RTTNews
07:01AM EDT  Scholar Rock Holding Q2 EPS $(0.65) Misses $(0.54) Estimate, Sales $3.90M Miss $6.82M Estimate   Benzinga
07:00AM EDT  Scholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress   Business Wire
04:02AM EDT  Earnings Scheduled For August 7, 2020   Benzinga
Aug 5, 2020
04:05PM EDT  Scholar Rock to Present at the 2020 Wedbush PacGrow Healthcare Conference   Business Wire
Aug 3, 2020
07:30AM EDT  Scholar Rock to Announce Second Quarter 2020 Financial Results and Introduce Newest Members of Management August 7, 2020   Business Wire
Jul 16, 2020
07:35AM EDT  Scholar Rock Appoints Edward Myles As CFO And Head Of Business Operations   RTTNews
07:32AM EDT  Scholar Rock Names Ted Myles CFO   Benzinga
07:30AM EDT  Scholar Rock Appoints Edward (Ted) Myles as Chief Financial Officer and Head of Business Operations   Business Wire
Jul 14, 2020
07:33AM EDT  Scholar Rock Appoints Tony Kingsley As President And CEO   RTTNews


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC